Bryan E. Shepherd

Bryan E. Shepherd

Auto-generated profile, based on publicly available information

Bryan E. Shepherd

Department of Biostatistics Vanderbilt University Nashville Tennessee USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2017 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
QLQi Liu
Qi Liu
BSBryan E. Shepherd
Bryan E. Shepherd
CLChun Li
Chun Li
FHFrank E. Harrell
Frank E. Harrell

13 November 2017 in Biometrics
Verified
Journal Article
Closed access
PDF file
QLQi Liu
Qi Liu
CLChun Li
Chun Li
VWValentine Wanga
Valentine Wanga
BSBryan E. Shepherd
Bryan E. Shepherd

23 March 2021 in Biometrics
Verified
Journal Article
Closed access
PDF file
SESvetlana Eden
Svetlana Eden
CLChun Li
Chun Li
BSBryan E. Shepherd
Bryan E. Shepherd

1 August 2009 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
STSuely H Tuboi
Suely H Tuboi
MSMauro Schechter
Mauro Schechter
CMCatherine C McGowan
Catherine C McGowan
CCCarina Cesar
Carina Cesar
AKAle Krolewiecki
Ale Krolewiecki
BSBryan E Shepherd
Bryan E Shepherd
Background: Although nearly 2 million people live with HIV in Latin America and the Caribbean, mortality rates after initiation of highly active antiretroviral therapy (HAART) have not been well described. Methods: Five thousand one hundred fifty-two HIV-infected, antiretroviral-naive adults from clinics in Argentina, Brazil, Chile, Haiti, Honduras, Mexico, and Peru starting HAART during 1996-2007 were included. First-year mortality rates and their association with demographics, regimen, baseline CD4, and clinical stage were assessed. Results: Overall 1-year mortality rate was 8.3% [95% confidence interval (CI): 7.6% to 9.1%], although variable across sites: 2.6%, 3.7%, 6.0%, 13.0%, 10.8%, 3.5%, and 9.8% for clinics in Argentina, Brazil, Chile, Haiti, Honduras, Mexico, and Peru, respectively. Eighty percent of deaths occurred within the first 6 months. Median baseline CD4 was 107 cells per milliliter, ranging from 79 (Peru) to 163 (Argentina). Mortality estimates adjusting for CD4 were similar across sites (1.1%-2.8% for CD4 = 200), except for Haiti, 7.5%, and Honduras, 7.0%. Death was associated with lower CD4 [adjusted hazard ratio for CD4 = 200 vs. CD4 = 50 was 0.58; 95% CI: 0.40 to 0.85] and clinical AIDS (hazard ratio = 3.1; 95% CI: 2.1 to 4.5). Conclusions: Mortality rates were similar to those reported elsewhere for resource-limited settings. Disease stage at HAART initiation, treatment eligibility criteria, program age, and background mortality rates may explain some variability in prognosis between sites.

15 December 2005 in Biometrics
Verified
Journal Article
Closed access
PDF file
BSBryan E. Shepherd
Bryan E. Shepherd
PGPeter B. Gilbert
Peter B. Gilbert
YJYannis Jemiai
Yannis Jemiai
ARAndrea Rotnitzky
Andrea Rotnitzky

19 June 2013 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
BSBryan E. Shepherd
Bryan E. Shepherd
MBMeridith Blevins
Meridith Blevins
LVLara M. E. Vaz
Lara M. E. Vaz
TMTroy D. Moon
Troy D. Moon
AKAaron M. Kipp
Aaron M. Kipp
Sten H. VermundSten H. Vermund
Sten H. Vermund
Patient retention is critical to the management of chronic diseases such as human immunodeficiency virus (HIV); hence, accurate measures of loss to follow-up (LTF) are important. Many different LTF definitions have been proposed. In a cohort of 9,692 HIV-infected patients initiating antiretroviral therapy in Mozambique from 2006 to 2011, we investigated the impact of the definition of LTF on estimated rates of LTF, acquired immunodeficiency syndrome (AIDS)-defining events, and death by applying 17 different definitions of LTF gleaned from HIV literature. We further investigated the impact of 4 specific components of the LTF definitions. Cumulative incidences of LTF and AIDS-defining events were estimated by treating death as a competing risk; Kaplan-Meier techniques and variations to account for informative censoring were used to estimate rates of mortality. Estimates of LTF 2 years after treatment initiation were high and varied substantially, from 22% to 84% depending on the LTF definition used. Estimates of 2-year mortality varied from 11% to 16%, and estimates of 2-year AIDS-defining events varied from 6% to 8%. As seen here, the choice of LTF definition can greatly affect study conclusions and program evaluations. Selection of LTF definitions should be based on the study outcome, available data on clinical encounters, and the patients' visit schedules; we suggest some general guidelines.